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Abstract: Most current guidelines recommend that older adults and the elderly strive for a 
total calcium intake (diet and supplements) of 1,000 to 1,300 mg/day to prevent 
osteoporosis and fractures. Traditionally, calcium supplements have been considered safe, 
effective and well tolerated, but their safety has recently been questioned due to potential 
adverse effects on vascular disease which may increase mortality. For example, the 
findings from a meta-analysis of randomized controlled trials (currently published in 
abstract form only) revealed that the use of calcium supplements was associated with an 
∼30% increased risk of myocardial infarction. If high levels of calcium are harmful to 
health, this may alter current public health recommendations with regard to the use of 
calcium supplements for preventing osteoporosis. In this review, we provide an overview 
of the latest information from human observational and prospective studies, randomized 
controlled trials and meta-analyses related to the effects of calcium supplementation on 
vascular disease and related risk factors, including blood pressure, lipid and lipoprotein 
levels and vascular calcification.  
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1. Introduction 
Maintaining an adequate calcium intake through dietary sources or supplements is widely regarded 
as a safe and effective strategy for the prevention and treatment of osteoporosis. In both 
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postmenopausal women and older men calcium supplementation or increased dietary calcium through 
fortified milk has been shown to slow or prevent bone loss at common fracture sites such as the hip 
and spine  [1-5]. It is likely that these positive effects on bone density translate into anti-fracture 
efficacy, as the findings from a recent meta-analysis of randomized controlled trials (RCTs) in adults 
aged 50 years and older reported that calcium supplementation or combined calcium and vitamin D 
supplementation reduced the relative risk of fractures by 12% [6]. At present, most dietary guidelines 
recommend that older adults and the elderly aim for a habitual total calcium intake (diet and 
supplements) of 1,000 to 1,300 mg per day. These requirements are based largely on data from calcium 
balance studies and the determination of the ‘maximal calcium retention’ or the threshold value at 
which balance does not further improve as intake increases [7]. However, recent data based on calcium 
intakes around predicted zero balance suggests that calcium requirements should be in the range of 741 
to 1035 mg/d for healthy adults, regardless of age or sex  [8]. While it is beyond the scope of this 
review to debate the specific merits associated with the determination of calcium requirements for 
adults, it is important to highlight that many elderly people do not obtain sufficient calcium through 
dietary sources alone. As a result, calcium supplements are widely recommended and have 
traditionally been considered a safe alternative to meeting calcium requirements. The most common 
side effects relate to bloating, constipation and more uncommonly, a slightly increased risk of kidney 
stones  [9]. 
Over the past two decades there has been a growing body of evidence to suggest that the use of 
calcium  [13-19] or calcium-vitamin D supplements  [10-12] may lead to a number of non-skeletal 
health benefits, including beneficial effects on cardiovascular disease (CVD) and related risk factors, 
type 2 diabetes, certain cancers and even mortality. For instance, several clinical trials and meta-
analyses have reported that calcium supplementation may improve serum lipids concentrations [15-17] 
and blood pressure  [18,19]. Based on these findings, one might expect that increased calcium would 
have protective effects on various cardiovascular endpoints, such myocardial infarction (MI), coronary 
heart disease (CHD) or stroke. However, there is emerging data from various studies (observational, an 
RCT and a meta-analysis) that long-term use of calcium supplements in healthy older adults, 
particularly women, may not be safe because it could have an adverse effect on cardiovascular 
outcomes  [20-22]. Because ageing is also associated with an increased incidence of CVD, even a 
slight increase in adverse vascular events would be clinically important because it might 
counterbalance any beneficial effects of calcium supplements in preventing osteoporosis and fractures. 
This review provides an overview of the latest evidence relating to the effects of calcium 
supplementation on vascular disease and related risk factors and associated mortality in the elderly. 
Several reviews have recently evaluated the impact of dairy foods on cardiovascular disease 
risk  [23,24], and thus we will not focus on their potential effects. However, the general consensus 
from these reviews is that dairy food consumption is not associated with a higher risk of CVD.  
2. Calcium Supplementation, Cardiovascular Disease and Mortality 
There have been a number of large observational epidemiological and prospective studies which 
have investigated the association between calcium intake and calcium supplement use, and 
cardiovascular disease risk and related mortality in older women and men. Typically, the findings from Nutrients 2010, 2                                       
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these studies indicate either a neutral effect  [25-27] or a modest protective effect of a high total 
calcium intake against vascular disease and even mortality  [10,14,28]. With regard to the specific 
effects of calcium supplements however, most studies to date have reported a non-significant effect. 
For example, in a prospective study of 34,486 postmenopausal Iowa women aged 55–69 years 
followed for 8 years, the relative risk of ischemic heart disease (IHD) mortality was 0.67 (95% CI, 
0.47–0.94) for women in the highest compared to lowest quartile for total calcium intake (diet + 
supplements)  [14]. In contrast, for women (n = 56) taking >500 mg/d of calcium supplements there 
was no significant risk reduction [multivariate relative risk (RR) 0.88 (95% CI, 0.64, 1.23)]  [14]. 
Similar non-significant findings with regard to calcium supplement use were reported in a 12 year 
prospective study in 39,800 men aged 40–75 years enrolled in the Health Professionals Follow 
Study  [25]. In this study, the multivariate RR for developing IHD in the highest quintile of calcium 
supplement use (median 1000 mg/d) compared with non-users was 0.87 (95% CI, 0.64, 1.19); the RR 
for nonfatal MI and IHD were 1.02 (95% CI, 0.71, 1.46) and 0.61 (95% CI, 0.34, 1.10), 
respectively  [25]. Two other large studies also reported that the RR of stroke was no different in men 
or women who received 400 mg/d or more of supplemental calcium compared with non-users  [26,27]. 
Data from a small study of acute hip fracture patients showed that the use of prescribed calcium and 
vitamin D supplements post-fracture was associated with a 36% and 43% reduction in death in women 
and men, respectively, after 3 years  [28]. Contrary to all these findings, a recent prospective study in 
10,555 Finnish women aged 52-62 years who were free of coronary heart disease (CHD) at baseline 
and followed for a mean of 6.55 years, reported that women using calcium supplements (or calcium 
plus vitamin D) had a 24% increased risk of CHD compared to non-users [1.24 (95% CI, 1.02, 
1.52)]  [21]. It is somewhat difficult to explain these findings given that the average age of the women 
was 57 years, and those taking supplements had a lower BMI, were more often non-smokers or former 
smokers and had less diabetes and hypertension mortality than non-users.  
Although there are no RCTs that have specifically evaluated the effect of calcium supplement use 
on CVD events or related mortality, a number of studies have pre-specified or performed secondary 
analyses to assess the effect of calcium supplementation on various cardiovascular endpoints, 
including MI, stroke, CHD, sudden death or their combination (Table 1). Of these, the findings from a 
recent preplanned secondary analysis of a 5-year RCT of 1471 healthy, elderly postmenopausal 
women who received calcium citrate (1,000 mg/d) or placebo has received the most attention because 
it has raised concerns about the cardiac safety for supplemental calcium   [20]. However, an 
accompanying editorial highlighted that data from this study were not totally consistent, and thus must 
be interpreted cautiously  [29]. In the analysis based on self-report and then adjudication by physicians 
(verified), those receiving calcium supplementation had a increased risk of MI (RR self report 2.24, p 
< 0.001; RR verified 2.12, p < 0.05) and the composite endpoint of MI, stroke or sudden death (RR 
self report 1.66, p < 0.01; RR verified 1.47, p = 0.08)  [30] (Figure 1). When the authors then searched 
the New Zealand hospital database of hospital admissions to identify additional vascular events that 
might have been missed, no statistically significant differences were detected between the calcium and 
placebo groups for either MI [RR 1.49 (95% CI, 0.86. 2.57)] or the composite endpoint [RR 1.21 (95% 
CI, 0.84, 1.74)]  [30] (Figure 1). However, rate ratio analysis revealed a trend for an increased risk of 
MI (1.67, p = 0.058) and the composite endpoint (1.43, p = 0.043). These findings do not provide 
conclusive evidence, although surprisingly the authors maintain that ‘..there are reasonable grounds Nutrients 2010, 2                                       
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for doubting the safety of calcium supplements..’ and suggest ‘.. there should be a reappraisal of their 
role in the management of osteoporosis..’   [31]. This view is not universally shared. Other 
investigators have raised concerns about various aspects of this study, including the relatively small 
number of vascular events and the wide confidence intervals, the borderline significance of many of 
the findings, and the failure to consider other important confounders, including serum   
25-hydroxyvitamin D   [32,33]. It is therefore critical that the results from other similar calcium 
supplementation studies be considered when evaluating the clinical and public health significance of 
these findings.   
Figure 1. Summary of the relative risk for myocardial infarction (MI) and the composite 
endpoint of MI, stroke or sudden death based on self report, verified (reported events 
verified by a physician) and confirm events (includes verified events and events obtained 
from the New Zealand national database on hospital admissions) in healthy 
postmenopausal women in the calcium supplementation compared to placebo group 
involved in the Auckland Calcium Study  [20]. 
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A summary of the key findings from the various RCTs that have evaluated the effects of calcium 
supplementation or combined calcium-vitamin D supplementation on cardiovascular related endpoints 
is presented in Table 1. In all these previous RCTs (with the exception of the Auckland study) there 
were no statistically significant adverse (nor beneficial) effects of calcium supplementation on CVD 
risk. For example, in an Australian study of 1460 postmenopausal women aged ≥70 years who were 
randomized to take calcium carbonate (1,200 mg/d) or placebo for 5 years, Prince et al.  [3] reported 
that incident IHD was no different between the supplemented and placebo group [HR 1.12 (95% CI, 
0.77,1.64)]. Similarly, secondary analysis of a 4-year RCT in 1179 postmenopausal women aged >55 
years in the United States found no excess occurrence of MI or other vascular events in the calcium 
treated (1,400–1,500 mg/d calcium citrate or carbonate) compared to placebo group  [34]. However, 
the participants in this study were ~10 years younger than the Auckland women. Despite this, it is Nutrients 2010, 2                                       
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intriguing that both these trials were similar to the Auckland study in terms of their design, study 
duration, number of participants and baseline calcium intakes (∼850–1,000 mg/d), but failed to observe 
any significant adverse effects. In addition, the dose of calcium was less in the Auckland study   
(1,000 mg/d versus 1,200–1,500 mg/d). However, one possible explanation for the contrasting results 
may relate to the type of calcium supplements used. Women in the Auckland trial consumed calcium 
citrate, whereas calcium carbonate was used in the Australian study and carbonate or citrate in the US 
trial. Calcium citrate has been reported to have superior bioavailability compared with calcium 
carbonate  [35], and leads to a greater acute rise in ionized calcium concentration  [36]. These findings, 
together with the fact that calcium carbonate must be taken with meals, may be one explanation for the 
contrasting results. Differences in serum 25-hydroxyvitamin D [25OHD] levels may also be a 
contributing factor given that low vitamin D has been associated with an adverse cardiovascular risk 
profile and increased risk of CV events   [37,38]. Serum 25OHD levels were not reported in the 
Auckland study, but in the Australian and US trials levels ranged from a mean of 67 to 72 nmol/L. 
When evaluating the potential adverse effects of calcium supplement use on vascular events and 
related mortality, it is also worth considering data from two of the largest trials [RECORD study and 
the Women’s Health Initiative (WHI)] that were designed to examine the effects of calcium carbonate 
and/or vitamin D on fracture incidence  [39,41]. In both these studies, no significant overall effect of 
supplement use on cardiovascular event rates or mortality was observed  [10,39,41]. The RECORD 
Study did not report vascular events, but there were no differences in death rates between calcium 
supplement users and non-users (17.7% vs. 16.2%)  [39]. In the WHI trial involving over 36,000 
postmenopausal women, the HR was 1.04 (95% CI, 0.92–1.18) for MI or CHD death  [41] and 0.91 
(95% CI, 0.83, 1.01) for total mortality  [10]. There was a trend for an increase in a composite end-
point of MI, death from CHD, coronary artery bypass graft or percutaneous coronary intervention [HR 
1.08 (95%CI 0.99–1.18)]  [41]. A major limitation of this study is that over 50% of the women were 
using non-study calcium supplements. Interestingly, when the analysis was restricted to women not 
self administering calcium, there was a 17% significant increased risk of MI or coronary 
revascularization [HR 1.17 (95% CI, 1.01, 1.36)]  [22]. However, in a subsequent study the authors 
reported that in women younger than 70 years of age, there was a trend toward a reduction in the risk 
of total, cardiovascular and cancer mortality in those receiving calcium plus vitamin D 
supplementation  [10]. When interpreting these findings and those from the RECORD study, it is 
important to consider the use of vitamin D given the evidence that supplemental vitamin D may reduce 
cardiovascular disease risk and all-cause mortality  [43]. Other potential important confounding factors 
must also be considered when evaluating the results of the WHI study, including non-compliance and 
the use of HRT. Nutrients 2010, 2                                       
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Table 1. Summary of the results from randomised controlled trials that evaluated the effects of calcium supplementation or 
combined calcium-vitamin D supplementation on cardiovascular related endpoints.  
Reference Participants Age  Intervention  Mean 
Dietary Ca 
Mean 
Total Ca 
†
Duration Primary  Study 
Endpoint 
Adverse event 
recording method
Key Findings 
Baron et 
al. [13]. 
930 men and 
women 
(recent 
history of 
colorectal 
adenomas) 
Mean 
61 yrs 
Calcium carbonate, 
1200 mg/d (n = 
464); placebo (n = 
466). 
Ca, 889 
mg/d; 
placebo, 865 
mg/d. 
Ca, ~2089 
mg/d 
4 yrs  Recurrent 
colorectal 
adenoma 
incidence 
Hospitalized 
events 
The number of participants 
hospitalized for cardiac events 
was no different between the Ca 
supplemented (n = 50, 11%) and 
placebo group (n = 46, 10%). 
Death rates were also similar 
between the groups (5% each in 
the calcium and placebo group).  
Grant et 
al. [39]. 
5292 men 
and women 
 
≥70 
yrs 
Calcium carbonate, 
1000 mg/d + 
vitamin D3, 800 
IU/d (n = 1306); 
calcium carbonate, 
1000 mg/d (n = 
1311); vitamin D3, 
1000 IU/d (n = 
1343); placebo (n = 
1332).  
Not reported -  2 yrs to 
62 
months 
Low energy 
trauma fracture 
incidence 
Self reported 
adverse events, 
death. 
No differences in death rates 
between the four groups: Ca+Vit 
D (16.9%); Vit D3 (16.2%); Ca 
(18.5%); placebo (16.3%), or the 
combined Ca vs. non-Ca groups 
(17.7% vs. 16.2%).  
Brazier et 
al. [40]. 
192 women  >65 
yrs 
Calcium carbonate, 
1000 mg/d + 
vitamin D, 800 IU/d 
(n = 95); placebo (n 
= 96). 
Ca + Vit D, 
752 mg/d; 
placebo, 721 
mg/d. 
Ca + Vit 
D, ~1752 
mg/d 
1 yr  Bone density, 
biochemical 
markers 
Self reported and 
observed adverse 
events. 
No difference in adverse 
cardiovascular events or death 
between the participants in the 
Ca+Vit D (n = 6) and placebo 
group (n = 5).   Nutrients  2010, 2                                       
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Table 1. Cont. 
Prince et 
al. [3]. 
1460 women  >70 
yrs 
Calcium carbonate, 
1200 mg/d (n = 
730); placebo (n = 
730). 
Ca, 915 
mg/d; 
placebo, 897 
mg/d. 
Ca, ~2115 
mg/d 
5 yrs  Clinical incident 
fractures, 
vertebral 
deformity and 
adverse events 
Self reported 
adverse events 
recorded in a dairy 
every 4 months.  
Incident ischemic heart disease 
was no different between the Ca 
(56 participants, 7.7%) and 
placebo group (51 participants, 
7.0%); HR, 1.12 (95% CI 0.77-
1.64). 
Hsia et 
al. [41]. 
36,282 
postmenopau
sal women 
50 to 
79 yrs 
Calcium carbonate, 
1000 mg/d + 
vitamin D3, 400 
IU/d (n = 18,176); 
placebo (n = 
18,106).  
Diet and 
supplements
; Ca, 1148 
mg/d; 
placebo, 
1154 mg/d. 
Ca, ~2148 
mg/d 
7 yrs  Fracture 
incidence 
Medical review of 
self reported 
events; adjudicated 
by centrally trained 
physicians 
No differences between the 
Ca+Vit D and placebo group for 
various CV events (RR): 
MI/CHD, 1.04 (95% CI 0.92, 
1.18); MI, 1.05 (95% CI, 0.91, 
1.20); CHD death, 1.01 (95% 
CI, 0.79, 1.29); stroke, 0.95 
(95% CI, 0.83, 1.10); transient 
ischemic attack, 1.16 (95% CI, 
0.95, 1.42).   
Bolland et 
al. [20]. 
1471 
postmenopau
sal women) 
Mean 
74 yrs 
Calcium citrate, 
1000 mg/d (n = 
732); placebo (n = 
739). 
Ca, 861 
mg/d; 
placebo,   
853 mg/d. 
Ca, ~1861 
mg/d 
5 yrs  Bone density and 
fracture incidence
Self reported 
adverse events, 
review of hospital 
records and death 
certificates; search 
of national 
database of 
hospital 
admissions for CV 
events. 
For verified vascular events, the 
RR in the Ca vs placebo groups 
were as follows: MI 1.49 (95% 
CI, 0.86, 2.57); stroke 1.37 (95% 
CI, 0.83, 2.28); sudden death 
0.51 (95% CI, 0.13, 2.01); MI, 
stroke or sudden death 1.21 
(95% CI, 0.84, 1.74).   Nutrients  2010, 2                                       
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Table 1. Cont. 
Reid et 
al. [4]. 
323 men  ≥40 
yrs 
Calcium citrate, 
1200 mg/d (n = 
108); calcium 
citrate, 600 mg/d (n 
= 108); placebo (n = 
107). 
Ca (1200 
mg/d), 930 
mg/d; Ca 
(600 mg/d), 
870 mg/d; 
placebo, 800 
mg/d. 
Ca (1200 
mg/d), 
∼2130 
mg/d; Ca 
(600 
mg/d), 
∼1470 
mg/d 
2 yrs  Bone density  Self reported 
adverse events.  
No difference between Ca 
groups and placebo for 
composite vascular events 
(angina, MI, sudden death, 
coronary revascularization) (p = 
0.24); Ca 1200 mg/d (n = 3); Ca 
600 mg/d (n = 2), placebo (n = 
0).  
Lappe et 
al. [34]. 
1179 
postmenopau
sal women 
>55 
yrs 
Calcium citrate or 
carbonate (1400-
1500 mg/d) + 
vitamin D (1000 
IU/d) (n = 446); 
calcium (as above) 
+ vitamin D placebo 
(n = 445); double 
placebo (n = 288). 
Diet and 
supplements
, mean Ca, 
1072 mg/d. 
Ca, ∼2400 
mg/d 
4 yrs  Fracture 
incidence 
Self reported 
adverse events  at 
6 monthly 
intervals, which 
were then verified 
by the participants 
physician.  
Vascular event rate in the two 
Ca treatment groups combined 
was no different from the 
placebo group (4.76 events/1000 
person year vs. 6.94 events/1000 
person year).  
Zhu et 
al. [42]. 
120 women  70-80 
yrs 
Calcium carbonate, 
1200 mg/d + 
vitamin D2, 1000 
IU/d (n = 39); 
Calcium carbonate, 
1200 mg/d + 
placebo vitamin D2 
(n = 40), placebo 
calcium and vitamin 
D (n = 41) 
Ca + vit D, 
927 mg/d; 
Ca 1054 
mg/d; 
placebo, 
1046 mg/d. 
Ca + Vit 
D, ∼2127 
mg/d; Ca, 
∼2254 
mg/d 
5 yrs  Bone density and 
biochemical 
markers 
Self reported 
adverse events 
There were no significant 
differences among the three 
groups in the rate of incident 
vascular disease (data not 
reported).  
† Mean total calcium (Ca) intake represents the estimated intake based on the mean baseline dietary calcium intake combined with the dose of 
supplemental calcium used in the intervention.   Nutrients 2010, 2                                       
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In light of the emerging concern that a high supplemental calcium intake may be associated with an 
increased risk for cardiovascular events, two recent studies have reviewed the available calcium 
supplementation RCTs that included cardiovascular endpoints  [22,44]. Wang et al.  [44] conducted a 
systematic review of prospective studies and RCTs that examined calcium supplementation, vitamin D 
supplementation or both on subsequent cardiovascular events. When the data from the RCTs were 
combined, the RR for CVD was 1.14 (95% CI, 0.92, 1.41) for calcium supplements versus placebo, 
and 1.04 (95% CI, 0.92, 1.18) for combined calcium plus vitamin D versus double placebo. There was 
also no significant effect of vitamin D supplementation on CVD [RR 0.90 (95% CI, 0.77, 1.05)]  [44]. 
Based on these findings, the authors concluded that calcium supplements seem to have minimal 
cardiovascular effects, but a limitation of this study is that only a small number of trials were included 
in the meta-analysis. A more recent and comprehensive meta-analysis included a larger number of 
trials (n = 15), with patient-level data available for five studies (n = 8151), and trial-level data for 11 
studies (n = 11,921) with a mean follow-up of 4 years  [22]. The inclusion criteria for this study were 
placebo controlled trials >12 months in duration with a calcium supplement dose >500 mg/d and at 
least 100 participants  [22]. For participants allocated to calcium supplements, the HRs for MI were 
1.31 (95% CI, 1.02, 1.67) and 1.27 (95% CI, 1.01, 1.59) for the patient- and trial- level data, 
respectively. This indicates that the use of calcium supplements was associated with an ∼30% increase 
in cardiovascular disease risk. However, since these results are currently only available in abstract 
form, it is difficult to provide a more comprehensive evaluation of the methodology and   
study findings.  
3. Calcium Supplementation, Lipids and Blood Pressure 
If the use of calcium supplements is associated with an increased risk of cardiovascular disease, one 
might expect that other common cardiovascular risk factors, such as cholesterol, lipids and blood 
pressure, would also be adversely affected. Contrary to this hypothesis, the findings from a number of 
clinical trials have shown that calcium supplementation was associated with improvements in serum 
lipids concentrations, particularly in women  [15-17]. This effect is reported to be due to the binding of 
calcium to fatty acids and bile acids in the intestines, which leads to a reduction in fat 
absorption  [16,45]. It has also been proposed that a reduction in parathyroid hormone (PTH) and/or 
1,25-dihydroxyvitamin D following calcium supplementation may lead to a decrease in intracellular 
calcium which reduces calcium flux into adipocytes   [46]. This may then inhibit lipogenesis and 
promote lipolysis  [46], leading to lower adiposity and thus favorable effects of lipid and lipoprotein 
levels. This proposed effect of calcium on adipocyte lipid metabolism, along with the reported pressor 
effects of calcium on vascular smooth muscle cells  [47], may also explain the findings that calcium 
supplementation can lower the risk of hypertension. Results of several meta-analyses of RCTs indicate 
that calcium supplementation can lead to small but significant reductions in both systolic and diastolic 
blood pressure  [18,19], with the greatest blood-pressuring lowering effects observed in those with the 
lowest baseline calcium intakes ( < 600–800 mg/d) before supplementation  [19,48] and/or those who 
are hypertensive  [49]. Based on these findings, it would appear that any potential adverse effects of 
calcium on cardiovascular endpoints are unlikely to be secondary to changes in either lipids or   
blood pressure.  Nutrients  2010, 2                                       
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4. Calcium Supplementation and Vascular Calcification 
Vascular calcification is a marker of sub-clinical atherosclerotic disease, and an independent 
predictor of subsequent vascular morbidity and mortality in men and women, including CHD, CVD 
and mortality  [50]. In patients with kidney disease, there is evidence from clinical trials showing that 
the use of calcium supplements is associated with increased vascular calcification  [51]. For example, 
the results from a 12 month trial in 200 hemodialysis patients comparing calcium acetate or carbonate 
with a non-calcium based binder (sevelamer) showed that calcium supplementation lead to a more 
rapid increase in both coronary and aortic calcification  [52]. In the Auckland Calcium Study, the 
authors speculated that the upward trends in cardiovascular event rates could be related to the age of 
the participants and their associated reduction in renal function  [20]. The mean glomerular filtration 
rate (GRF) of the women in this study was 61 (SD 11) mL/min  [31], which indicates that a portion of 
women had impaired renal function. In 90 pre-dialysis patients with a mean GRF of ~30 mL/min, 
supplementation with calcium carbonate for an average of 2 years resulted in a significant increase in 
coronary artery calcification (CAC), but these changes in total calcium scores (TCS) were not 
significantly different from controls (178 vs. 205)  [53]. Therefore, it is questionable whether impaired 
renal function is a likely reason for the increased vascular risk in the postmenopausal women receiving 
calcium in the Auckland trial.  
In apparently healthy older men and women, there are few studies which have investigated the 
effects of increased calcium on the progression of vascular calcification. Bhakta et al.  [54] conducted 
a retrospective analysis in a subgroup of participants (n = 257) enrolled in the prospective 
Epidemiology of Coronary Artery Calcification study in Minnesota who were aged >60 years and had 
complete 4-year follow-up on aortic value calcification (AVC) as assessed by electron beam computed 
tomography (EBCT). In women, the progression of AVC or CAC over a mean of 3.7 years was no 
different between those who reported using calcium supplements (n = 25) and those who did not  
(n = 114); no men in the study reported using calcium supplements. Similarly, the findings from a 2-
year RCT involving 163 healthy men aged 57 ± 10 years who had taken 1200 mg/d of supplemental 
calcium or placebo revealed that supplementation was not associated with an increase in coronary 
calcification assessed by computed tomography (CT)  [55]. In contrast, in a retrospective analysis of a 
2-year RCT, we reported that supplementing the diet with calcium and vitamin D3 fortified milk   
(1,000 mg/d and 800 IU/d) may accelerate abdominal aortic calcification (AAC) measured by CT in 
older men, but only in those who presented with AAC prior to the commencement of the study  [56]. 
In this subgroup of men, who had a mean dietary calcium intake at study entry of ~900 mg/d, the mean 
AAC scores increased significantly in the milk relative to control group [mean change (95%CI); 24 (7, 
42); controls 6 (-5, 18), P < 0.05], independent of age, BMI, anti-hypertensive or lipid-lowering 
medication use, smoking, exercise or blood pressure  [56]. It is difficult to explain these results given 
that there were no differences between the fortified milk and control groups for changes in weight, fat 
mass, blood pressure, lipids, serum calcium, GFR, fat or saturated fat intake. In addition, baseline 
serum 25OHD levels were ~75 nmol/L, and increased further following supplementation which might 
be expected to have a protective effect. 
The development of vascular calcification is a complex process that is not only dependent on the 
physio-chemical effects of calcium and phosphate, but also on factors that can regulate the Nutrients  2010, 2                                       
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differentiation of smooth muscle cells to osteoblast-like cells; similar to those in osteogenesis. 
Potential mediators include both inhibitors [pyrophosphate; osteoprotegerin (OPG); osteopontin, 
matrix Gla protein (MGP), fetuin A, parathyroid hormone-related protein (PTHrP); fibroblast growth 
factor 23 (FGF 23)] and activators [phosphorus, calcium, alkaline phosphatase; bone morphogenetic 
protein 2, 1,25(OH)2D; osteocalcin; osteonectin; oxidized low density lipoprotein (LDL), advanced 
glycation end products (AGEs)] that regulate this process  [51]. Previous research has shown that 
serum OPG, which inhibits osteoclast differentiation and activity and stimulates osteoclast apoptosis, 
is related to cardiovascular events  [57], and the presence and/or severity of aortic calcification in 
patients undergoing
 haemodialysis  [58] or those with peripheral vascular disease  [59]. However, in 80 
healthy older women from the Auckland Calcium Study, no differences were observed for the changes 
in serum OPG and MGP in women treated with calcium or placebo for 5 years  [31].  
5. Calcium Supplementation and Cerebrovascular Disease Risk 
Some of the early work examining the relationship between calcium and cerebrovascular disease 
suggests that there may be a protective effect of calcium. For example, in an ecologic study of elderly 
people from the southwest of France, a high level of calcium in drinking water was associated with a 
lower risk of noncerebrovascular (10%) and cerebrovascular (14%) related death  [60]. Calcification of 
vascular smooth muscle has also been associated with brain lesions, which are a marker of 
cerebrovascular disease. In the elderly, there is some evidence that a high calcium intake is associated 
with brain lesions. Payne et al.  [61] examined the relationship between dietary calcium and vitamin D 
intakes and brain lesions, measured by MRI scans, in 232 elderly men and women (95 with current or 
prior depression, 137 without depression). They found that both calcium and vitamin D were positively 
associated with a higher total volume of brain lesions, even after controlling for potential confounders, 
including age, hypertension, diabetes, heart disease, kilocalories, group (depression or no depression), 
and lesion load (high or low). Furthermore, the authors’ earlier work found that individuals consuming 
high-fat dairy products (1.8 serves per day) had 1.5 times greater brain lesion volume than those 
consuming 0.3 serves per day  [62]. Although cause-and-effect cannot be established from these cross-
sectional studies, the apparent link between calcium and brain lesions warrants further research given 
that brain lesions have also been linked to an increased risk of cognitive impairment, dementia,   
and depression.                       
6. Calcium Supplementation and Kidney Stones 
Kidney stones have been linked to a high calcium intake, but this appears to depend on the source of 
calcium. Several prospective studies reported that a diet high in calcium is associated with a reduced 
risk of kidney stones, possibly by reducing gut absorption of oxalate which is one of the main 
components of kidney stones  [63,64]. In contrast, the use of calcium supplements has been associated 
with an increased risk, although these finding are not consistent. For instance, data from the 7-year 
Women’s Health Initiative (WHI) trial revealed that the risk of kidney stones (renal calculi) was 
increased by 17% in those receiving calcium and vitamin D supplements [HR 1.17 (95% CI, 1.02, 
1.34)   [9]. In contrast, a systematic review of calcium supplementation trials in postmenopausal 
women revealed that most studies show no increase in stone risk with a high calcium intake (diet or Nutrients  2010, 2                                       
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supplements), and in fact several trials reported an inverse association between calcium intake and 
stone risk  [65].  
7.  Serum Calcium and Cardiovascular Disease Risk 
It has been suggested that the increased risk of vascular disease with calcium supplementation may 
be related to serum calcium concentrations  [31]. There is indirect evidence to support this hypothesis. 
A number of observational and prospective studies in men and women have reported that serum 
calcium levels were related to the risk of MI   [66,67] and even death   [67]. Data from 40,538 
hemodialysis patients showed serum phosphorus concentrations >5.0 mg/dl were associated with an 
increased relative risk of death (RR, 1.07, 1.25, 1.43, 1.67, and 2.02 for serum phosphorus at 5.0 to 
6.0, 6.0 to 7.0, 7.0 to 8.0, 8.0 to 9.0, and ≥9.0 mg/dL)  [68]. Importantly, higher adjusted serum 
calcium concentrations were also associated with an increased risk of death, independent of serum 
phosphorus. In the same study, only moderate to severe hyperparathyroidism (PTH concentrations 
≥600 pg/mL), but not more modest increases in PTH, was associated with an increase in the relative 
risk of death. Hyperphosphatemia and hyperparathyroidism were significantly associated with all-
cause, cardiovascular, and fracture-related hospitalization in dialysis patients. 
A recent post-hoc data analysis from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial 
of raloxifene treatment in 7259 postmenopausal women with osteoporosis examined the associations 
between higher baseline calcium and phosphorus levels and incident cardiovascular events over 4 
years  [69]. After adjustment for multiple covariates, including 25(OH)D, parathyroid hormone, and 
phosphorus, adjusted hazard ratios (95% confidence interval) per SD of calcium were significantly 
increased for combined cardiovascular outcomes [AHR 1.17 (95% CI, 1.01-1.35), p = 0.03], but were 
either marginal for cerebrovascular events [1.22 (95% CI, 0.99-1.49), p = 0.06], or not significant for 
coronary heart disease [1.12 (95% CI, 0.92-1.37), p = 0.25], and death [1.18 (95% CI, 0.94-1.48),  
p = 0.16]. Associations between serum phosphorus and cardiovascular events did not persist after 
adjustment for additional confounders. Thus, there was an independent association between higher 
serum calcium levels, but not higher serum phosphorus levels, and higher rates of cardiovascular 
events in postmenopausal women with osteoporosis. It is interesting to speculate that greater increases 
in serum calcium resulting from calcium citrate than calcium carbonate may be responsible for the 
findings in the Auckland study of postmenopausal women. 
8. Conclusion 
In conclusion, the findings from this review that evaluated the results from observational and 
prospective studies, RCTs and meta-analyses, highlight the heterogeneity of findings regarding 
whether the use of calcium supplements has any adverse effects of health, including kidney stones, 
vascular disease and mortality. In terms of CVD and its related risk factors, the vast majority of studies 
have failed to observe any significant adverse effect of calcium supplement use. However, the findings 
from a recent meta-analysis of published RCTs (currently published in abstract form only) that 
included most of the key calcium supplementation trials having cardiovascular events as secondary 
outcomes, provide the most compelling data to support the notion that the use of calcium supplements 
may increase the risk of MI in postmenopausal women [22]. While these findings are of concern, the Nutrients  2010, 2                                       
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clinical and public health implications need to be carefully considered. What is the key message for 
physicians, health care professionals and patients? We believe that it would be unwise at this point to 
recommend that older women avoid or stop taking their calcium supplements. Unfortunately, this may 
well be the key message conveyed when the findings from this meta-analysis are published.  
When evaluating whether calcium supplements adversely affect vascular disease, it is important to 
consider that total calcium intakes may exceed 2,000 to 2,500 mg per day (1,000–1,200 mg/d 
supplemental calcium plus 800–1,000 mg/d dietary calcium). At these levels, there may well be some 
cause for concern, but several important questions still remain. Is the level of risk the same for all 
women or is it greatest in those already at high risk of CVD? Does the level of risk vary by the type of 
calcium supplement used, particularly those that led to greater elevations of serum calcium 
concentrations, and does the addition of vitamin D counteract this increased risk? Is there a threshold 
level of calcium above which intakes become detrimental to health? Although there is currently no 
evidence to support such a threshold, a recent study in healthy adult men and women aged 19 to 75 
years which was designed to determine the level of dietary calcium to maintain neutral calcium 
balance, reported that the calcium requirements (or recommended dietary allowance) for men and 
women should be approximately 1035 mg/d   [8]. While some have questioned the balance-based 
approach used to estimate the average calcium requirements in this study  [70], these findings provide 
some evidence that daily calcium requirements may be lower than previously estimated.  
It is evident from the above discussion that there are still many important unanswered questions that 
need to be addressed before women are advised to stop taking their calcium supplements. 
Unfortunately it is unlikely that there will ever be a long-term RCTs conducted to address whether the 
use of calcium supplements is associated with increased vascular disease because the primary 
hypothesis would be one of harm  [31]. Therefore, large cohort prospective studies comparing groups 
with habitually high versus low calcium intakes (or those regularly taking calcium supplements) will 
be important to gain an insight into the long-term effects of high calcium intakes on vascular disease 
and related mortality. Until then, we recommend that healthy older women adhere to the current 
guidelines which typically recommend a total calcium intake of 1,000 to 1,300 mg/d, which can be 
readily achieved through both dietary sources and the addition of calcium supplements, when required.  
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